TCR T-cell therapy (ImmunoScape/PureMHC)

N/A

Report date: 2025/03/20 09:41:28

Base Information

Drug NameTCR T-cell therapy (ImmunoScape/PureMHC)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionHuman leukocyte antigen modulators

TargetsHuman leukocyte antigen

Therapy Area/IndicationsLung NeoplasmsColorectal NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunoScape Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmunoScape Pte Ltd Pure Mhc

Inactive CompaniesN/A

Active IndicationsLung NeoplasmsColorectal Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A